AstraZeneca Shares Fall 9% After Heart Drug Wainua Fails Late-Stage Trial

AstraZeneca (AZN) shares plummeted as much as 9% on Wednesday after the pharmaceutical giant announced its experimental drug Wainua failed to meet its primary endpoint in a key late-stage trial. The decline put the stock on track for its most significant one-day drop in years.

Trial Disappoints Expectations

The study evaluated Wainua as an add-on to standard treatment for patients with a progressive heart disease. According to the company, the drug did not significantly reduce the risk of death or major cardiovascular complications compared to the existing standard of care alone.

The result was a major setback for a drug that investors had largely expected to succeed. AstraZeneca developed Wainua in partnership with Ionis Pharmaceuticals Inc (IONS).

Market Impact and Analyst Outlook

The news sent ripples through the market, with AstraZeneca's London-listed shares becoming the biggest drag on the FTSE 100 index in early trading. Analysts at Morgan Stanley described the outcome as a "meaningful downside surprise," noting that most investors had anticipated a positive result.

Ad

The brokerage highlighted that consensus forecasts had projected approximately $3.3 billion in risk-adjusted peak annual sales for Wainua in this specific heart disease indication. Following the trial's failure, these estimates are expected to be revised materially lower, potentially leading to a mid-single-digit percentage reduction in AstraZeneca's longer-term earnings expectations.

Next Steps for the Pipeline

With the future of Wainua for this indication now uncertain, investor focus is expected to shift to other promising candidates in AstraZeneca's late-stage pipeline. Key upcoming catalysts include data for lung cancer treatment Dato-DXd, chronic obstructive pulmonary disease drug tozorakimab, and breast cancer therapy camizestrant.

AstraZeneca and Ionis stated that detailed results from the Wainua study will be presented at the European Society of Cardiology Congress in August following a more thorough analysis of the full dataset.